No profile data available.
Alzamend Neuro, Inc. (ALZN) is a healthcare company in the brain and nerve treatment drugs industry, based in Atlanta, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2026, and net income of -$8.77 million. In Q1 2027 (the quarter ended July 31, 2026) revenue was $0. Its market capitalization was $6.47 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended April 30, 2026; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Alzamend Neuro reported $0 in revenue for fiscal year 2026. In Q1 2027 revenue was $0.
$6.47 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Brainstorm Cell Therapeutics Inc. (BCLI), Reviva Pharmaceuticals Holdings, Inc. (RVPH), Enveric Biosciences, Inc. (ENVB), Silo Pharma, Inc. (SILO).